SR One, the venture capital arm of GlaxoSmithKline, focuses on investing in innovative life science companies globally. The firm primarily targets Series A and Series B funding rounds, with additional investments in later stages such as Series C and D. SR One's investment strategy is centered on backing companies with strong fundamentals and novel approaches to addressing diseases, aiming to translate cutting-edge science into transformative medical treatments.
Notable portfolio companies include Adarx Pharmaceuticals, Avalyn Pharma, Nimbus Therapeutics, and Odyssey Therapeutics. The firm is led by experienced partners who bring a wealth of industry expertise and connections, enhancing their ability to support portfolio companies beyond capital investment. SR One offers a unique "back-and-build" approach, providing strategic guidance and leveraging its extensive network to help startups navigate the complexities of drug development and commercialization.
Sr One - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Top Investment Stages
Stage Mix
Concentration shown as share of disclosed investments by stage.
Sr One - Classification
- Also Known As
- Sr One Limited
- NAICS
- 520000Finance and Insurance
- 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
- 523900Other Financial Investment Activities
- 523990All Other Financial Investment Activities
- 523999Miscellaneous Financial Investment Activities
- SIC
- 6700Holding And Other Investment Offices
- 6790Miscellaneous Investing
- 6799Investors, Not Elsewhere Classified
Show 8 more industry codes
- NAICS
- 540000Professional, Scientific, and Technical Services
- 525000Funds, Trusts, and Other Financial Vehicles
- 541000Professional, Scientific, and Technical Services
- 523910Miscellaneous Intermediation
- SIC
- 6000Depository Institutions
- 7300Business Services
- 6720Investment Offices
- 6722Management Investment Offices, Open-end































